- Home
- ABTC vs KNSA Comparison
ABTC vs KNSA Comparison
Compare ABTC & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTC | KNSA |
|---|---|---|
| Founded | 2024 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ABTC | KNSA |
|---|---|---|
| Price | $0.91 | $48.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $4.00 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 12.3M | 539.0K |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $92.72 | $38.01 |
| Revenue Next Year | $40.46 | $17.42 |
| P/E Ratio | ★ $5.78 | $65.09 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $0.77 | $18.26 |
| 52 Week High | $10.24 | $49.33 |
Technical Indicators
Market Signals| Indicator | ABTC | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 62.30 |
| Support Level | N/A | $41.55 |
| Resistance Level | $1.24 | N/A |
| Average True Range (ATR) | 0.07 | 1.66 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 43.56 | 89.75 |
Price Performance
Historical ComparisonAbout ABTC American Bitcoin Corp.
American Bitcoin Corp is a Bitcoin accumulation platform focused on building America's Bitcoin infrastructure platform. The Company delivers institutional-grade exposure to Bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.